Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-04-19
2005-04-19
Leary, Louise N. (Department: 1654)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S029000, C424S570000, C424S569000
Reexamination Certificate
active
06881546
ABSTRACT:
Methods and compositions are disclosed that are useful for the prevention and/or treatment of cardiovascular and cardiac diseases and disorders, or damage resulting from surgical or medical procedures that may cause ischemic or ischemic/reperfusion damage in humans; and cardiovascular trauma. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that interfere with the production and/or biological activities of sphingolipids and their metabolites, particularly sphingosine (SPH) and sphingosine-1-phosphate (S-1-P). Also disclosed are methods for identifying and isolating therapeutic agents.
REFERENCES:
patent: 4150949 (1979-04-01), Smith
patent: 4816450 (1989-03-01), Bell et al.
patent: 4937232 (1990-06-01), Bell et al.
patent: 5079263 (1992-01-01), Zeeck et al.
patent: 5137919 (1992-08-01), Igarashi et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5248824 (1993-09-01), Igarashi et al.
patent: 5260288 (1993-11-01), Igarashi et al.
patent: 5331014 (1994-07-01), Kimura et al.
patent: 5369030 (1994-11-01), Hannun et al.
patent: 5391800 (1995-02-01), Igarashi et al.
patent: 5430169 (1995-07-01), Boumendjel et al.
patent: 5444087 (1995-08-01), Patel et al.
patent: 5585476 (1996-12-01), MacLennan et al.
patent: 5631394 (1997-05-01), Wei et al.
patent: 5663404 (1997-09-01), Igarashi et al.
patent: 5677288 (1997-10-01), Marangos
patent: 5677337 (1997-10-01), Wei et al.
patent: 5851782 (1998-12-01), Hannun et al.
patent: 5912144 (1999-06-01), Au-Young et al.
patent: 5919687 (1999-07-01), Chatterjee
patent: 5929039 (1999-07-01), Woodcock et al.
patent: 5989803 (1999-11-01), Tabas et al.
patent: 6051598 (2000-04-01), Shayman et al.
patent: 6057126 (2000-05-01), Munroe et al.
patent: 6130067 (2000-10-01), Tsui
patent: 6140060 (2000-10-01), Chun et al.
patent: 6187562 (2001-02-01), Duckworth et al.
patent: 6210976 (2001-04-01), Sabbadini
patent: 6284798 (2001-09-01), Amtmann et al.
patent: 6306911 (2001-10-01), Wachter et al.
patent: 6323201 (2001-11-01), Carson et al.
patent: 6534322 (2003-03-01), Sabbadini
patent: 20010041688 (2001-11-01), Werber et al.
patent: 2000293181 (2000-10-01), None
patent: WO 9744019 (1997-11-01), None
patent: WO 9803529 (1998-01-01), None
patent: WO 9828445 (1998-07-01), None
patent: WO 9907855 (1998-08-01), None
patent: WO 9840349 (1998-09-01), None
patent: WO 9912890 (1999-03-01), None
patent: WO 9916888 (1999-04-01), None
patent: WO 9933972 (1999-07-01), None
patent: WO 9938983 (1999-08-01), None
patent: WO 9941265 (1999-08-01), None
patent: WO 9941266 (1999-08-01), None
patent: WO 9946277 (1999-09-01), None
patent: WO 9961581 (1999-12-01), None
patent: WO 0000593 (2000-01-01), None
patent: WO 0021919 (2000-04-01), None
patent: WO 0052173 (2000-09-01), None
patent: WO 00 56135 (2000-09-01), None
patent: WO 0058448 (2000-10-01), None
patent: WO 0058491 (2000-10-01), None
patent: WO 0059517 (2000-10-01), None
patent: WO 9857179 (2000-10-01), None
patent: WO 0070028 (2000-11-01), None
patent: WO 0072833 (2000-12-01), None
patent: WO 0104108 (2001-01-01), None
patent: WO 0104139 (2001-01-01), None
patent: WO 0107418 (2001-02-01), None
patent: WO 0131029 (2001-05-01), None
patent: WO 01 37836 (2001-05-01), None
patent: WO 0138295 (2001-05-01), None
patent: WO 0155410 (2001-08-01), None
patent: WO 0157057 (2001-08-01), None
patent: WO 0160990 (2001-08-01), None
patent: WO 01 71045 (2001-09-01), None
patent: WO 0172701 (2001-10-01), None
patent: WO 0180903 (2001-11-01), None
patent: WO 0185953 (2001-11-01), None
Sabbadini et al., “The MIRF trial: Predicting the incidence of severity of CAD using serum sphinglipids.” Circulation, 102: 11699, 2000 (Abstract).
Nakajima et al., “Expression and characterization of Edg-1 receptors in rat cardiomyocites: Calcium deregulation in response to sphingosine 1-phosphate.” European Journal of Biochemistry 267: 5679-5686, 2000.
Huwiler et al., “Physiology and pathophysiology of sphingolipid metabolism and signaling.” Biochimica Et Biophysica Acta, 1485: 63-99, 2000.
International Search Report issued in PCT Application No. PCT/US01/50785.
Abe, et al., “Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase,”Kidney International, 57:446-454 (2000).
Abe, et al., “Structural and stereochemical studies of potent inhibitors and glucosylceramide synthase and tumor cell growth,”Journal of Lipid Research, 36:611-621 (1995).
Abe, et al., “Use of Sulfobutyl Ether β-Cyclodextrin as a Vehicle for D-threo-1-Phenyl-2-decanoylamino-3-morpholinipropanol-Related Glucosylceramide Synthase Inhibitors,”Analytical Biochemistry, 287:344-347 (2000).
An, et al., “Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysosphosphotatidic Acit,”J. Biol. Chem., 273:7906-7910 (1998).
An, et al., “Identification of cDNAs encoding two G protein-coupled receptors for lysophingolipids,”FEBS Letts., 417:279-282 (1997).
An, et al., “Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5,”J. Biol. Chem., 275:288-296 (2000).
Ancellin, et al., “Extracelluar export of sphingosine kinase-1 enzyme: Sphingosine 1 phosphate generation and the induction of angiogenic vascular maturation,”JBC Papers in Press, Published Dec. 10, 2001 (manuscript M102841200).
Andrieu-Abadie, et al., “L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation,”FASEB J., 13:1501-1510 (1999).
Arenz, et al., “Manumycin A and its Analogues Are Irreversible Inhibitors of Neutral Sphingomyelinase,”ChemiBiochem., 2:141-143 (2001).
Arenz, et al., “Synthese des ersten selektiven irreverilben Inhibitors der neutralen Sphingomyelinase,”Angew Chem., 112:1498-1500 (2000) (GERMAN).
Arenz, et al., “Synthesis and Biochemical Investigation of Scyphostatin Analogues as Inhibitors of Neutral Sphingomyelinase,”Bioorganic&Medicinal Chemistry, 9:2901-2904 (2001).
Arenz, et al., “Synthesis of the First Selective Irreversible Inhibitor of Neutral Sphingomyelinase,”Eur. J. Org. Chem., 137-140 (2001).
Ariga, et al., “Role of Sphingolipid-mediated cell death in neurodegenerative disease,”Journal of Lipid Research, 39:1-16 (1998).
Bajjalieh, et al., “Ceramide Kinase,”Methods in Enzymology, 311:207-215 (1999).
Bawab, et al., “Molecular Cloning and Characterization of a Human Mitochondrial Ceramidase,”J. Biol. Chem., 275:21508-21513 (2000).
Bernardo, et al., “Purification and Characterization of a Magnesium-dependent Neutral Sphingomyelinase from Bovine Brain,”J. Biol. Chem., 275:7641-7647 (2000).
B tto, t al., “Sphingosylphosphocholine modulates the ryanodine receptor/calcium-release channel of cardiac sarcoplasmic reticulum membranes,”Biochem. J., 322:327-333 (1997).
Bielawska, et al., “(1S, 2R)-D-erhthro-2-(N-Myristoylamino)-1-phenyl-1-propanol as an Inhibitor of Ceramidase,”J. Biol. Chem., 271:12646-12654 (1996).
Bielawska, et al., “Ceramide Is Involved in Triggering of Cardiomyocyte Apoptosis Induced by Ischemia and Reperfusion,”Am. J. Pathol., 151(1257-1263 (1997).
Boudker, et al., “Detection and Characterization of Ceramide-1-phosphate Phosphatase Activity in Rat Liver Plasma Membrane,”J. Biol. Chem., 268:22150-22155 (1993).
Brady, et al., “The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease,”Proc. Natl. Acad. Sci. USA, 55(2):366-369 (1966).
Brindley, et al., “Analysis of Ceramide 1-phosphate and Sphingosine-1-phosphate Phosphatase Activities,”Methods in Enzymology, 311:233-244 (1999).
Brownlee, C., “Intracellular signalling: sphingosine-1-phosphate branches out,”Current Biology, 11:R535-R538 (2001
Biotechnology Law Group
Chambers Daniel M
Leary Louise N.
Medlyte, Inc., SDSU Heart Institute
LandOfFree
Compositions and methods for the treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3439599